Merck & Co., Inc. (MRK) Stock Price Today
Aura AI Summary
Key Stats
- $305.12BMarket Cap
- -Volume
- HealthSector
- $129.5252W High
- $77.6052W Low
- -Typical Hold Time
- $348.54BEnterprise Value
- 2.75%Div Yield
- -Trading Activity
Track Merck & Co., Inc. (MRK) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Merck & Co., Inc. has traded between a low of $77.6 and a high of $129.52, highlighting its annual price range. Buy and sell Merck & Co., Inc. shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Most Recent News
Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.
The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.
Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

Alamar Biosciences launches national study using blood tests to advance Alzheimer's biomarker research.
Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.